Oncology · Antibody–drug conjugate (ADC)

Sacituzumab tirumotecan

Sacituzumab tirumotecan is a TROP2-directed antibody–drug conjugate developed by Merck under license from Kelun-Biotech. It is approved in China, where Kelun markets it, and in the TroFuse-005 trial it improved overall survival in previously treated endometrial cancer. It is under FDA priority review and not yet approved in the United States.

Approved outside the U.S.Approved in China since 2024; under FDA priority review for previously treated endometrial cancer, decision date June 15, 2027 (company-reported)

Approved outside the U.S.: Approved by a regulator outside the United States, such as the European Commission, but not by the FDA. About status badges

FDA: Not approved. No approved application appears in openFDA as of — (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperMerck & Co. (MSD) (partners: Sichuan Kelun-Biotech (originator)) · Merck & Co. pipeline
Drug typeAntibody–drug conjugate (ADC)
TargetTROP2 (trophoblast cell-surface antigen 2)
MechanismAn antibody that seeks out the TROP2 protein on cancer cells and delivers a chemotherapy payload directly into them
Other namessac-TMT, MK-2870, SKB264

Key points

  • Antibody–drug conjugates attach a potent chemotherapy to an antibody, aiming to deliver the drug to cancer cells while sparing healthy tissue.
  • In the 776-patient TroFuse-005 trial in previously treated endometrial cancer, median overall survival was 19.0 months versus 12.1 months with chemotherapy chosen by the physician (hazard ratio 0.68).
  • Merck reports that the FDA accepted its application for priority review, with a target action date of June 15, 2027 (company-reported).
  • The FDA selected sac-TMT for a Commissioner's National Priority Voucher in December 2025, which offers the possibility of an expedited review (company-reported).
  • China's NMPA approved it in November 2024 for previously treated advanced triple-negative breast cancer; Kelun reports four approved indications in China as of August 2026, across breast and lung cancer (company-reported).
  • More than 100 registered trials are testing it across lung, breast, gynecologic, and other cancers, many of them in China.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Endometrial cancer
BLA based on TroFuse-005; FDA target action date June 15, 2027 (company-reported).
Submitted (priority review; company-reported)3
3 active · 0 completed
90.6% eventual approval
Application → approval: 90.6%
Lung cancer
Multiple Phase 3 trials in lung cancer (registry). Approved in China for EGFR-mutant NSCLC after prior treatment (company-reported).
Phase 338
38 active · 0 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Breast cancer
Multiple Phase 3 trials in breast cancer, including triple-negative disease (registry). Approved in China for previously treated triple-negative and HR+/HER2- breast cancer (company-reported).
Phase 327
26 active · 1 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Other cancers (cervical, ovarian, gastric and more)
Includes cervical, ovarian, and gastric cancer trials (registry).
Phase 360
59 active · 1 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What sacituzumab tirumotecan is

Sacituzumab tirumotecan (sac-TMT) is an antibody–drug conjugate (ADC). It is an antibody that recognizes TROP2, a protein found on the surface of many solid tumors, chemically linked to a potent chemotherapy payload. The antibody carries the payload to TROP2-bearing cancer cells, where it is released to kill them. The idea is to concentrate chemotherapy where it is needed.

Sac-TMT was originated by Sichuan Kelun-Biotech. Merck develops it under an exclusive license and collaboration agreement and, according to its SEC filings, retains decision-making authority over development and commercialization.

Clinical evidence: TroFuse-005

TroFuse-005 enrolled 776 patients with advanced or recurrent endometrial cancer whose disease had progressed after platinum-based chemotherapy and immunotherapy. They were randomized to sac-TMT or chemotherapy chosen by the physician. Results were published in The Lancet in October 2026:

Measure Sac-TMT Physician's choice
Median progression-free survival 7.2 months 3.9 months
Progression-free survival hazard ratio 0.59
Median overall survival 19.0 months 12.1 months
Overall survival hazard ratio 0.68
Grade 3 or higher adverse events 69% 57%

The overall survival benefit, a nearly seven-month improvement in median survival, is the strongest kind of evidence in oncology. Treatment-related deaths were rare and similar between groups (under 1% each).

Regulatory status

China: the National Medical Products Administration (NMPA) granted marketing authorization in November 2024 for adults with unresectable locally advanced or metastatic triple-negative breast cancer who had received at least two prior systemic therapies, at least one for advanced disease. Kelun-Biotech describes it as the first domestically developed ADC fully approved for marketing in China. By August 2026, Kelun reported four approved indications in China, covering previously treated triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and HR-positive, HER2-negative breast cancer, with more applications under review (company-reported).

United States: Merck reports that the FDA accepted its Biologics License Application for patients with endometrial cancer previously treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor, under priority review, with a target action date of June 15, 2027. The FDA had selected sac-TMT for a Commissioner's National Priority Voucher in December 2025. Merck has said it hopes for approval before the target date (company-reported). openFDA lists no approved application yet.

Scientific perspective

ADCs have become one of oncology's most productive drug classes, and TROP2 is one of their most contested targets. TroFuse-005 is notable because it showed an overall survival benefit in a randomized trial against active treatment, rather than relying on response rates or progression-free survival alone. The higher rate of serious side effects is typical of ADCs, which still deliver chemotherapy, and will be weighed against the survival gain.

Development perspective

  • Next milestone: the FDA decision for endometrial cancer, due by June 15, 2027 (company-reported). Historically, about 90.6% of applications that reach the FDA are eventually approved. That is an industry-wide average, not a prediction.
  • Breadth: the registry lists more than 100 trials, including several large Phase 3 studies in lung and breast cancer. Many are run in China, where Kelun leads development.
  • Partnership: Merck's filings note a separate funding agreement with Blackstone for part of sac-TMT's development costs, which does not change Merck's control of the program.

Development timeline

  1. Jan 5, 2024TroFuse-005 begins randomizing patients with previously treated endometrial cancer. Peer-reviewed
  2. Nov 27, 2024Kelun-Biotech announces China NMPA marketing authorization for adults with unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic therapies. Company-reported
  3. Dec 2025FDA selects sac-TMT for a Commissioner's National Priority Voucher. Company-reported
  4. Aug 17, 2026Kelun-Biotech reports four approved indications in China: previously treated triple-negative breast cancer, EGFR-mutant lung cancer, and HR+/HER2- breast cancer. Company-reported
  5. Oct 26, 2026TroFuse-005 published: overall survival 19.0 vs 12.1 months (HR 0.68) and progression-free survival 7.2 vs 3.9 months (HR 0.59). Peer-reviewed
  6. Nov 4, 2026Merck reports its application is under FDA priority review for previously treated endometrial cancer, with a June 15, 2027 target date. Company-reported

What could change the outlook

  • The FDA decision, due by June 15, 2027. Merck has said it hopes for approval before that date (company-reported).
  • Phase 3 readouts in lung and breast cancer, which would determine whether sac-TMT becomes a broad oncology product.
  • Safety: grade 3 or higher adverse events occurred in 69% of patients on sac-TMT in TroFuse-005, versus 57% on chemotherapy.
  • Competition from other TROP2-directed antibody–drug conjugates.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Sacituzumab tirumotecan. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedOct 29, 2026

    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

    “The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline.

    Source
    SEC Form 8-K · Financial results
  2. RegulatoryCompany-reportedOct 27, 2026

    New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application ("the application") for its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱...

    Company
    Sichuan Kelun-Biotech
  3. Trial resultsCompany-reportedOct 25, 2026

    Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the prespecified final overall survival (OS) analysis results of the Phase III OptiTROP-Lung04 study of sacituzumab...

    Company
    Sichuan Kelun-Biotech

All Sacituzumab tirumotecan disclosures in Pipeline News

Clinical trials

129 registered trials list Sacituzumab tirumotecan as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Endometrial cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
TroFuse-033 · NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3Recruiting1,123 (est.)May 24, 2032 (est.)No
TroFuse-005 · NCT06132958
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Phase 3Active, not recruiting710 (est.)Jan 10, 2028 (est.)No
MK-2870-001 · NCT04152499
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Phase 1/2Active, not recruiting1,410Nov 30, 2025No

Lung cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3Recruiting851 (est.)Jan 12, 2029 (est.)No
TroFuse-019 · NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Phase 3Recruiting780 (est.)Feb 21, 2034 (est.)No
TroFuse-007 · NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Phase 3Recruiting614 (est.)Jan 25, 2028 (est.)No
NCT06074588
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Phase 3Active, not recruiting556 (est.)May 10, 2027 (est.)No
NCT06305754
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Phase 3Active, not recruiting550 (est.)Aug 17, 2028 (est.)No
NCT07895992
SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
Phase 3Not yet recruiting490 (est.)Dec 30, 2028 (est.)No
NCT06711900
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3Active, not recruiting432 (est.)Dec 2026 (est.)No
NCT06670196
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3Active, not recruiting420 (est.)May 2027 (est.)No
NCT06448312
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3Active, not recruiting406 (est.)Nov 2026 (est.)No
NCT05870319
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Phase 3Active, not recruiting376Jul 11, 2024No
NCT05816252
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
Phase 2Active, not recruiting356Aug 31, 2026No
NCT07697586
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Phase 2Recruiting206 (est.)Aug 2028 (est.)No
NCT07750704
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
Phase 2Not yet recruiting153 (est.)Sep 2029 (est.)No
NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/2Recruiting140 (est.)Aug 17, 2029 (est.)No
NCT07375316
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Phase 2Recruiting120 (est.)Jun 30, 2028 (est.)No
NCT05351788
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 2Recruiting110 (est.)Aug 2026 (est.)No
NCT07854509
A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure
Phase 2Not yet recruiting110 (est.)Dec 30, 2027 (est.)No
NCT06788912
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Phase 2Active, not recruiting60 (est.)Feb 6, 2032 (est.)No
NCT07789444
Sacituzumab Tirumotecan(Sac-TMT) and Brain Radotherapy for EGFR+ NSCLC With Brain Mets
Phase 2Not yet recruiting53 (est.)Jul 1, 2027 (est.)No
NCT07108816
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
Phase 2Not yet recruiting52 (est.)Dec 30, 2026 (est.)No
NCT06706219
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
Phase 2Not yet recruiting50 (est.)Nov 30, 2028 (est.)No
NCT07197008
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
Phase 2Not yet recruiting50 (est.)Dec 30, 2027 (est.)No
PROTECT-2 · NCT06992739
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2Recruiting49 (est.)Mar 2027 (est.)No
NCT07193160
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Phase 2Not yet recruiting45 (est.)Jul 1, 2026 (est.)No
NCT07343479
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Phase 2Not yet recruiting45 (est.)Jun 20, 2027 (est.)No
NCT07670013
SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study
Phase 2Recruiting43 (est.)Jan 2028 (est.)No
TianjinCIH · NCT07438600
Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
Phase 2Not yet recruiting38 (est.)Feb 28, 2027 (est.)No
NCT07703228
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
Phase 2Active, not recruiting38 (est.)Sep 30, 2027 (est.)No
NCT07323056
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Phase 2Recruiting36 (est.)Jun 1, 2026 (est.)No
STAR-01 · NCT07501169
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2Not yet recruiting33 (est.)Aug 31, 2027 (est.)No
NCT07244926
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Phase 2Not yet recruiting31 (est.)Jun 2027 (est.)No
NCT07329322
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Phase 2Recruiting30 (est.)Aug 31, 2027 (est.)No
SKB264-ANLO · NCT07388875
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
Phase 2Not yet recruiting30 (est.)Feb 1, 2027 (est.)No
NCT07819578
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC
Phase 2Not yet recruiting30 (est.)Dec 1, 2028 (est.)No
NCT07545213
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
Phase 2Not yet recruiting27 (est.)Feb 15, 2028 (est.)No
TROP-LUNG · NCT07548060
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Phase 2Recruiting25 (est.)Jan 22, 2028 (est.)No
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
TroFuse-008 · NCT06049212
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Phase 1Active, not recruiting30 (est.)Dec 31, 2027 (est.)No
NCT07702305
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
Phase 1Not yet recruiting15 (est.)Dec 31, 2027 (est.)No

Breast cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06966700
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3Recruiting2,400 (est.)Mar 23, 2033 (est.)No
NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3Recruiting1,530 (est.)Dec 16, 2030 (est.)No
NCT06312176
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase 3Recruiting1,200 (est.)Jul 11, 2027 (est.)No
NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Phase 3Recruiting1,000 (est.)May 18, 2030 (est.)No
NCT06279364
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3Active, not recruiting537Apr 2027 (est.)No
NCT07071337
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Phase 3Recruiting430 (est.)Jul 2027 (est.)No
STARTER · NCT07628504
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
Phase 3Not yet recruiting420 (est.)Mar 30, 2030 (est.)No
NCT06081959
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3Recruiting376 (est.)Dec 31, 2026 (est.)No
NCT05347134
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Phase 3Active, not recruiting254 (est.)Nov 30, 2023No
NCT07738341
GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
Phase 1/2Recruiting270 (est.)Aug 1, 2029 (est.)No
NCT05445908
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Phase 2Completed184Jul 31, 2026No
SHIFT-001 · NCT06849492
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
Phase 2Not yet recruiting120 (est.)Dec 31, 2027 (est.)No
NCT07139470
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Phase 1/2Not yet recruiting59 (est.)Apr 15, 2027 (est.)No
NeoSaciA · NCT07109284
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
Phase 2Not yet recruiting55 (est.)Jan 2028 (est.)No
NCT07054242
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Phase 2Not yet recruiting52 (est.)Oct 30, 2026 (est.)No
SHINE-HER · NCT07182721
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
Phase 2Recruiting48 (est.)Sep 30, 2028 (est.)No
NCT07153965
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase 2Not yet recruiting47 (est.)Sep 1, 2026 (est.)No
NCT07471776
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Phase 2Recruiting45 (est.)Mar 11, 2028 (est.)No
NCT07244874
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Phase 2Not yet recruiting41 (est.)Jan 30, 2028 (est.)No
ST-A-TN · NCT07371208
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
Phase 2Recruiting40 (est.)Aug 2028 (est.)No
BALISTA · NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Phase 2Recruiting39 (est.)Dec 31, 2026 (est.)No
NCT07007780
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
Phase 2Not yet recruiting35 (est.)Aug 31, 2026 (est.)No
NCT07258108
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
Phase 2Recruiting35 (est.)Jul 30, 2027 (est.)No
NCT07466927
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Phase 2Not yet recruiting30 (est.)Jan 15, 2028 (est.)No
BERLIN · NCT07458113
Sac-TMT for Active TNBC Brain Metastases
Phase 2Not yet recruiting20 (est.)Aug 2028 (est.)No
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06877416
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
N/ARecruiting700 (est.)Jan 1, 2026 (est.)No
NCT06993506
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
N/ARecruiting500 (est.)Aug 1, 2027 (est.)No

Other cancers (cervical, ovarian, gastric and more)

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Phase 3Recruiting1,023 (est.)Oct 29, 2031 (est.)No
TroFuse-021 · NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Phase 3Recruiting900 (est.)Feb 25, 2033 (est.)No
NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Phase 3Recruiting770 (est.)Apr 27, 2029 (est.)No
NCT06459180
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Phase 3Active, not recruiting686 (est.)Jun 15, 2028 (est.)No
TroFuse-031 · NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Phase 3Recruiting590 (est.)Jul 27, 2029 (est.)No
TroFuse-015 · NCT06356311
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Phase 3Active, not recruiting473Oct 19, 2026No
TroFuse-055 · NCT07829783
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Phase 3Recruiting400 (est.)Nov 17, 2031 (est.)No
NCT07586943
SKB118 Injection in Advanced Solid Tumors
Phase 1/2Recruiting530 (est.)Dec 2029 (est.)No
NCT05631262
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Phase 2Active, not recruiting321Dec 30, 2026 (est.)No
CVL006-T1002 · NCT07157956
CVL006 Combination Therapy in Advanced Solid Tumors
Phase 1/2Not yet recruiting318 (est.)Aug 12, 2028 (est.)No
NCT06780111
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Phase 1/2Recruiting298 (est.)Jan 4, 2032 (est.)No
TroFuse-01A · NCT07908524
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Phase 1/2Not yet recruiting290 (est.)Jun 29, 2032 (est.)No
NCT05642780
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Phase 2Active, not recruiting240 (est.)Nov 30, 2027 (est.)No
NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Phase 1/2Recruiting230 (est.)Jun 11, 2027 (est.)No
NCT06428409
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Phase 1/2Recruiting220 (est.)Oct 16, 2029 (est.)No
NCT06445972
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Phase 1/2Recruiting210 (est.)May 9, 2028 (est.)No
NCT07785609
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
Phase 2Recruiting200 (est.)Sep 30, 2031 (est.)No
NCT06469944
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Phase 1/2Recruiting160 (est.)Sep 12, 2029 (est.)No
NCT07252739
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2Recruiting140 (est.)Nov 15, 2029 (est.)No
RINGQUEST · NCT07716917
Genitourinary Tumors With Sacituzumab Tirumotecan
Phase 2Not yet recruiting100 (est.)Oct 2029 (est.)No
NCT07256236
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Phase 2Recruiting89 (est.)Jun 30, 2028 (est.)No
NCT07738757
SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies
Phase 2Not yet recruiting80 (est.)Sep 1, 2028 (est.)No
SPARE-UC-01 · NCT07662863
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
Phase 2Not yet recruiting75 (est.)Dec 1, 2028 (est.)No
NCT07701681
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruiting75 (est.)Sep 1, 2028 (est.)No
STRAP · NCT07521670
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
Phase 2Not yet recruiting68 (est.)Oct 31, 2028 (est.)No
Saint-Tropez · NCT07928193
Sac-TMT in Salivary Gland Cancers
Phase 2Not yet recruiting64 (est.)Apr 2030 (est.)No
NCT07128693
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
Phase 2Not yet recruiting60 (est.)Dec 2028 (est.)No
NCT07105852
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Phase 2Recruiting59 (est.)Jul 1, 2027 (est.)No
NCT07718854
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Phase 2Recruiting50 (est.)Sep 2036 (est.)No
ARCANA · NCT07804966
Sac-TMT in Vaginal and Vulvar Cancers
Phase 2Not yet recruiting48 (est.)Mar 2030 (est.)No
SKB264-Fru-GA · NCT07689292
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruiting45 (est.)Aug 31, 2027 (est.)No
NCT07579598
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
Phase 2Not yet recruiting40 (est.)Dec 31, 2026 (est.)No
NCT06145308
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2Recruiting39 (est.)Jul 10, 2028 (est.)No
NCT07088211
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Phase 2Recruiting39 (est.)Aug 1, 2027 (est.)No
NCT06483334
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Phase 1/2Active, not recruiting38 (est.)Mar 31, 2028 (est.)No
NCT07343453
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
Phase 2Not yet recruiting38 (est.)Dec 22, 2027 (est.)No
NCT07850791
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
Phase 2Recruiting38 (est.)Oct 2028 (est.)No
PERSEUS · NCT07815197
Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer
Phase 2Not yet recruiting37 (est.)Mar 2028 (est.)No
TroFuse-027 · NCT06637423
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Phase 1/2Completed35Sep 30, 2026No
XANTHOS · NCT07750353
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
Phase 2Not yet recruiting35 (est.)Dec 2029 (est.)No
NCT07701122
Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer
Phase 2Not yet recruiting33 (est.)Jul 1, 2027 (est.)No
NCT07823270
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2Not yet recruiting33 (est.)Dec 2028 (est.)No
Tsubomi · NCT07913568
A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell Carcinoma Previously Treated With Platinum-based Chemotherapy(NCCH2407/MK014)
Phase 2Not yet recruiting32 (est.)Jan 31, 2030 (est.)No
SCOPE · NCT07907861
Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy
Phase 2Not yet recruiting31 (est.)Jan 1, 2029 (est.)No
NCT07314619
Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
Phase 2Not yet recruiting30 (est.)Dec 30, 2027 (est.)No
NCT07324629
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Phase 2Recruiting30 (est.)Apr 2028 (est.)No
NCT07561463
Sacituzumab Tirumotecan for Pancreatic Cancer
Phase 2Not yet recruiting30 (est.)Jan 1, 2027 (est.)No
NCT07939204
A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy
Phase 2Not yet recruiting30 (est.)Dec 2027 (est.)No
NCT07179783
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Phase 2Recruiting28 (est.)Jun 30, 2027 (est.)No
NCT07729033
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
Phase 2Not yet recruiting28 (est.)Dec 2027 (est.)No
NCT07811752
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
Phase 2Recruiting28 (est.)Dec 31, 2027 (est.)No
METROPOLIS · NCT07720258
Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy
Phase 2Not yet recruiting27 (est.)Dec 31, 2028 (est.)No
NCT07348861
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
Phase 2Not yet recruiting25 (est.)Jan 1, 2028 (est.)No
NCT07341100
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Phase 2Active, not recruiting20 (est.)Jan 2028 (est.)No
NCT07438626
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
Phase 2Recruiting20 (est.)Jun 1, 2028 (est.)No
NCT07511023
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
Phase 2Not yet recruiting20 (est.)Mar 1, 2031 (est.)No
STOP-NEPC · NCT07639086
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
Phase 2Not yet recruiting20 (est.)Mar 31, 2030 (est.)No
NCT07686588
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2Not yet recruiting20 (est.)Dec 31, 2027 (est.)No
NCT07778368
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma
Phase 2Not yet recruiting20 (est.)Aug 31, 2028 (est.)No
1 Phase 1 or other early-stage study
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07068542
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
N/ARecruiting94 (est.)Dec 31, 2027 (est.)No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07623577
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Phase 2Recruiting24 (est.)Jan 2027 (est.)No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Kelun-Biotech. Sacituzumab tirumotecan approved for marketing by NMPA of China for 2L+ advanced or metastatic TNBC. PR Newswire, November 27, 2024.Company-reported
  2. Kelun-Biotech. 2026 interim results. PR Newswire, August 17, 2026.Company-reported
  3. Lorusso D, et al. Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial. The Lancet. 2026 (online October 26).Peer-reviewed
  4. Merck & Co., Inc. Form 10-Q for the quarter ended September 30, 2026.Company-reported
  5. Merck & Co., Inc. Form 10-Q (SEC EDGAR): sac-TMT license from Sichuan Kelun-Biotech.Company-reported
  6. ClinicalTrials.gov. TroFuse-005 (NCT06132958).Registry
  7. U.S. Food and Drug Administration. Development & Approval Process | Drugs.Regulator
  8. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.